Print
Email
Print Edition Stories
Monday, August 23, 2010
Alexion's R.I. site approved as second drug manufacturing site
By Michelle Lang
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc.’s Smithfield, R.I.-based manufacturing facility as a second source of commercial supply its drug Soliris, a treatment for paroxysmal nocturnal hemoglobinuria (PNH).
The Rhode Island site already has approval from the European Medicines Agency as a second source of Soliris supply in the European Union. The U.S. and the E.U. account for 90 percent of Alexion’s 2009 revenue, the company reported. Further applications for regulatory approval of the Rhode Island manufacturing site are in the works with other countries where Alexion is planning to commercialize Soliris.
PNH is a rare blood disorder that is potentially fatal. Currently, Soliris is the only drug approved specifically to treat PNH, Alexion officials noted in a press release, and it’s also being tested as a treatment for other rare disorders associated with nephrology and transplants.
Cheshire, Conn.-based Alexion Pharmaceuticals reported in July that its revenue and profits rose in the second quarter of the year, buoyed by the climb in revenue from Soliris.
In January, 2009, Alexion resolved an ongoing patent dispute with PDL BioPharma Inc. over Soliris. It paid $25 million to PDL BioPharma for rights to use some of PDL’s patent portfolio called the Queen in Soliris.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
